Omnicell, Inc.
Mar 24, 2015

Omnicell, Inc. Receives Expected Nasdaq Notification of Noncompliance

MOUNTAIN VIEW, Calif., March 24, 2015 /PRNewswire/ -- As indicated in a Form 8-K filed with the SEC on March 20, 2015, Omnicell, Inc. received a written notification from the NASDAQ OMX Group, Inc. on March 18, 2015, indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) for continued listing, due to the delay in filing its Annual Report on Form 10-K for the period ended December 31, 2014 beyond the extended filing due date of March 17, 2015. Under the Nasdaq continued listing rules, Omnicell has 60 calendar days to either file the Form 10-K or submit a plan to regain compliance. If the plan is accepted and Omnicell has not otherwise regained compliance by filing the Form 10-K, Nasdaq can grant an exception of up to 180 calendar days from the Form 10-K's due date, or until September 14, 2015, to regain compliance.

Omnicell, Inc. logo.

The Notice has no immediate effect on the listing of Omnicell's common stock on Nasdaq. Omnicell is currently working diligently to complete its internal investigation previously disclosed in the Form 12b-25 filed on March 2, 2015 and Form 8-K filed on March 17, 2015. Once the internal investigation process is complete, Omnicell plans to file the Form 10-K as soon as practicable thereafter.

About Omnicell

Since 1992, Omnicell (NASDAQ: OMCL) has been creating new efficiencies to improve patient care, anywhere it is delivered. Omnicell is a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire healthcare continuum— from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home.

More than 3,000 customers worldwide have utilized Omnicell Automation and Analytics solutions to increase operational efficiency, reduce errors, deliver actionable intelligence and improve patient safety. Omnicell Medication Adherence solutions, including its MTS Medication Technologies brand, provide innovative medication adherence packaging solutions to help reduce costly hospital readmissions. In addition, these solutions enable approximately 6,000 institutional and retail pharmacies worldwide to maintain high accuracy and quality standards in medication dispensing and administration while optimizing productivity and controlling costs.

For more information about Omnicell, Inc. please visit www.omnicell.com.

OMCL-E

Logo - http://photos.prnewswire.com/prnh/20120731/SF48971LOGO-a

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/omnicell-inc-receives-expected-nasdaq-notification-of-noncompliance-300055408.html

SOURCE Omnicell, Inc.

News Provided by Acquire Media